Equity · Healthcare
CADL
NASDAQCandel Therapeutics (CADL)
The line runs 11.81 USD on 13 August through 9.35 USD on 10 November, on a scale from 6 to 14. Days the market did not trade hold the previous close, flat.
- Market cap
- 715.4M USD
- EPS, diluted, year to Dec 2025
- −0.72 USD
- 52-week range
- 4.42 USD – 13.76 USD
- Avg volume
- 59.2K
as of Nov 10, 2026
Have Candel Therapeutics (CADL) insiders bought or sold shares recently?
In the 90 days to 11 Nov 2026, Candel Therapeutics insiders reported 3 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 23 Feb 2026.
Form 4, 90 days to 11 Nov 2026, newest reported trade 11 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 11 Sep 2026 | Tak Paul PeterChief Executive Officer | Sell | 59,379 | 621K USD |
| 10 Sep 2026 | Tak Paul PeterChief Executive Officer | Sell | 220,866 | 2.5M USD |
| 17 Aug 2026 | Tyagarajan SeshuChief Technology Officer | Sell | 7,000 | 84K USD |
| Sold | 3 open-market sales | 287,245 | $3.24M |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Sep 2026 | Tak Paul PeterChief Executive Officer | Option exercise | 125,000 | 194K USD |
Which funds hold Candel Therapeutics (CADL)?
1 of the 45 institutional funds we track reported a Candel Therapeutics position for the quarter ended 30 Sep 2026 — a combined 603K USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 57,800 | 603K USD |
What has been filed or recorded for Candel Therapeutics (CADL)?
The filings we hold for Candel Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 21,218 shares | 197K USD notional · 0.028% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.52 USD | |
| 30 Jun 2026 | Financials | Total assets | 208.1M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 126.1M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.14 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.72 USD | |
| 31 Dec 2025 | Financials | Net income | −38.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.72 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.21 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.09 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.13 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.74 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.33 USD |
What do people ask about Candel Therapeutics (CADL)?
What did Candel Therapeutics shares close at?9.35
Candel Therapeutics closed at 9.35 USD on 10 Nov 2026, down 1.68% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Candel Therapeutics’ market cap?715.4M
Candel Therapeutics is worth 715.4M USD by market value as of 10 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have Candel Therapeutics insiders bought or sold shares recently?3 sales
In the 90 days to 11 Nov 2026, Candel Therapeutics insiders reported 3 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 23 Feb 2026. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Candel Therapeutics?1 of 45
1 of the 45 funds we track reported a Candel Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Candel Therapeutics last report earnings?−0.52
Candel Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.52 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings